A securities class action lawsuit has been filed against Mereo BioPharma Group plc in the U.S., alleging violations of the Securities Exchange Act of 1934 and SEC Rule 10b-5. The suit claims the company made false and misleading statements during the period from June 5, 2023 to December 26, 2025 by concealing negative facts about its Phase 3 ORBIT and COSMIC programs, and later disclosed that neither program met its primary endpoint. Investors who bought shares during the class period are being urged to seek lead plaintiff status by April 6, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602201236PRIMZONEFULLFEED9658473) on February 20, 2026, and is solely responsible for the information contained therein.